Cite
Benenati S, Galli M, De Marzo V, et al. Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2021;7(2):86-93doi: 10.1093/ehjcvp/pvaa001.
Benenati, S., Galli, M., De Marzo, V., Pescetelli, F., Toma, M., Andreotti, F., Della Bona, R., Canepa, M., Ameri, P., Crea, F., & Porto, I. (2021). Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. European heart journal. Cardiovascular pharmacotherapy, 7(2), 86-93. https://doi.org/10.1093/ehjcvp/pvaa001
Benenati, Stefano, et al. "Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials." European heart journal. Cardiovascular pharmacotherapy vol. 7,2 (2021): 86-93. doi: https://doi.org/10.1093/ehjcvp/pvaa001
Benenati S, Galli M, De Marzo V, Pescetelli F, Toma M, Andreotti F, Della Bona R, Canepa M, Ameri P, Crea F, Porto I. Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2021 Mar 15;7(2):86-93. doi: 10.1093/ehjcvp/pvaa001. PMID: 31942965.
Copy
Download .nbib